Alexander Nolte's most recent trade in Syndax Pharmaceuticals Inc was a trade of 17,000 Stock Options (Right to buy) done . Disclosure was reported to the exchange on Feb. 2, 2023.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Syndax Pharmaceuticals Inc | Alexander Nolte | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 17,000 | 17,000 | - | - | Stock Options (Right to buy) | |
Syndax Pharmaceuticals Inc | Alexander Nolte | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 30,000 | 30,000 | - | - | Stock Options (Right to buy) | |
Syndax Pharmaceuticals Inc | Alexander Nolte | Chief Accounting Officer | Other type of transaction at price $ 12.39 per share. | 01 Feb 2022 | 968 | 968 (0%) | 0% | 12.4 | 11,994 | Common Stock |
Syndax Pharmaceuticals Inc | Alexander Nolte | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 16.65 per share. | 01 Feb 2022 | 968 | 0 (0%) | 0% | 16.6 | 16,117 | Common Stock |